通过雄激素受体阻断增强癌症免疫治疗。
Boosting anticancer immunotherapy through androgen receptor blockade.
机构信息
Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
Division of Melanoma, Sarcomas, and Rare Tumors, European Institute of Oncology, IRCCS, Milan, Italy.
出版信息
Cancer Cell. 2022 May 9;40(5):455-457. doi: 10.1016/j.ccell.2022.04.007.
PMID:35537411
Abstract
Immune checkpoint inhibitors (ICIs) have limited activity in patients with castration-resistant prostate cancer (CRPC). A Nature article demonstrates that androgen receptor (AR) negatively modulates CD8 T cell-driven antitumor immune response and that androgen-axis blockade is a promising therapeutic strategy to improve ICI activity in CRPC.
摘要
免疫检查点抑制剂（ICIs）在去势抵抗性前列腺癌（CRPC）患者中的活性有限。一篇《自然》杂志的文章表明，雄激素受体（AR）负向调节 CD8 T 细胞驱动的抗肿瘤免疫反应，雄激素轴阻断是提高 CRPC 中 ICI 活性的有前途的治疗策略。
Zotero 插件